LP
IONS icon

LMR Partners’s Ionis Pharmaceuticals IONS Stock Holding History

LMR Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.86M Buy
51,400
+31,400
+157% +$2.48M 0.01% 713
2025
Q4 		$1.58M Buy
+20,000
New +$1.51M ﹤0.01% 871

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's IONS Position: Q1 2026 in Review

LMR Partners held its Ionis Pharmaceuticals (IONS) position steady in Q1 2026 at 15,000 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #959.

LMR Partners first reported a position in IONS in Q3 2016 and has held it in 7 quarters since. The position peaked at $5.3M in Q3 2016. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • LMR Partners held 15,000 shares of Ionis Pharmaceuticals worth $1.13M as of Q1 2026.
  • LMR Partners left its Ionis Pharmaceuticals share count unchanged in Q1 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #959 holding.
  • LMR Partners first reported a position in Ionis Pharmaceuticals in Q3 2016 and has held it in 7 quarters since.
  • LMR Partners's Ionis Pharmaceuticals position peaked at $5.3M in Q3 2016.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.